## Translational Assessment: C9orf72 ASO Treatment for ALS/FTD
### Druggability & Feasibility
C9orf72 ASOs are among the most translationally advanced genetic interventions in ALS/FTD. Ionis and Biogen's **BIIB078 (ION364)** has completed Phase 1 testing (NCT04165729), establishing human safety and CSF exposure. ASOs are well-suited to CNS delivery via lumbar intrathecal injection, with established nonclinical packages. The mechanism is genetically validated—C9orf72 HRE accounts for ~40% of familial ALS and ~25% of FTD cases, representing a large, defined patient population with clear biomarker readouts (CSF DPR levels, NfL). Human proof-of-concept for target engagement is already in hand.
### Main Safety Concerns
The critical risk is **on-target toxicity from C9orf72 knockdown**. Complete loss of C9 haploinsufficiency is not benign—C9orf72 regulates lysosomal function and immune signaling. Phase 1 data for BIIB078 showed acceptable safety but **did not meet primary efficacy endpoints**, with some patients receiving higher doses showing trends toward clinical worsening (NCT04165729; Cogentix 2022). This raises the possibility that therapeutic windows are narrow. Additionally, ASOs require repeated intrathecal dosing indefinitely, creating cumulative exposure risk and substantial burden for progressive disease.
### Competitive Landscape
The field is actively diversifying beyond ASOs. **Wave Life Sciences (Suvodirsen/WVE-004)** pursued stereopure ASOs targeting splice-switching but discontinued after Phase 1 failed to show DPR reduction. Small molecule approaches targeting G-quadruplex interactions (e.g., cargo compounds) and RAN translation inhibitors remain preclinical. Gene editing strategies (base editing, CRISPRi) are earlier-stage but offer potentially durable benefit. The competitive advantage of ASOs is now primarily regulatory pathway clarity and manufacturing maturity, not necessarily mechanistic superiority.
### Key Translational Bottleneck
The core unresolved question—as the skeptic correctly identifies—is **whether TDP-43 pathology downstream of C9 is reversible**. Human imaging and fluid biomarkers for TDP-43 burden are still maturing. Without robust readouts of existing pathology reversal, distinguishing disease modification from simple target engagement remains difficult. Regulatory endpoints will require demonstrable clinical slowing, which ASO monotherapy may struggle to achieve given the complexity of ALS/FTD pathogenesis.
**Bottom line**: Mechanistically compelling and genetically validated, but BIIB078's Phase 1 readout tempers enthusiasm. The path forward likely requires combination approaches or more selective allele-targeting strategies rather than simple repeat knockdown.